NCT05042791View on ClinicalTrials.gov

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
HER2-positive Metastatic Breast Cancer
Interventions
COMBINATION_PRODUCT

radiation combined with pyrotinib and capecitabine

This study selects different radiation (SRT or WBRT) combined with pyrotinib and capecitabine to treat HER2-positive advanced breast cancer patients with brain metastases

Trial Locations (1)

330029

RECRUITING

Jiangxi Cancer Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER